Alexandra Boer Kimball
#139,273
Most Influential Person Now
Researcher
Alexandra Boer Kimball's AcademicInfluence.com Rankings
Alexandra Boer Kimballcomputer-science Degrees
Computer Science
#6583
World Rank
#6941
Historical Rank
Machine Learning
#2187
World Rank
#2215
Historical Rank
Artificial Intelligence
#2454
World Rank
#2495
Historical Rank
Database
#3670
World Rank
#3821
Historical Rank
Download Badge
Computer Science
Alexandra Boer Kimball's Degrees
- PhD Computer Science Stanford University
- Masters Computer Science Stanford University
Similar Degrees You Can Earn
Why Is Alexandra Boer Kimball Influential?
(Suggest an Edit or Addition)Alexandra Boer Kimball's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) (2008) (1672)
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. (2008) (834)
- IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2–dependent mechanisms with implications for psoriasis pathogenesis (2006) (638)
- Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. (2015) (620)
- Efficacy and safety of guselkumab, an anti‐interleukin‐23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double‐blinded, placebo‐ and active comparator–controlled VOYAGE 1 trial (2017) (591)
- The Psychosocial Burden of Psoriasis (2005) (473)
- Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. (2016) (448)
- National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. (2008) (429)
- Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials (2017) (386)
- Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa (2012) (366)
- Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. (2011) (288)
- Quantifying the harmful effect of psoriasis on health-related quality of life. (2002) (262)
- Text-message reminders to improve sunscreen use: a randomized, controlled trial using electronic monitoring. (2009) (256)
- The response of skin disease to stress: changes in the severity of acne vulgaris as affected by examination stress. (2003) (233)
- The US dermatology workforce: a specialty remains in shortage. (2008) (233)
- Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis. (2014) (229)
- Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies (2014) (211)
- Psoriasis: is the impairment to a patient’s life cumulative? (2010) (204)
- Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis. (2006) (200)
- North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management. (2019) (188)
- Cardiovascular Disease and Risk Factors among Psoriasis Patients in Two US Healthcare Databases, 2001–2002 (2008) (179)
- Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. (2010) (177)
- Long‐term efficacy of ustekinumab in patients with moderate‐to‐severe psoriasis treated for up to 5 years in the PHOENIX 1 study (2013) (177)
- Hidradenitis suppurativa: Epidemiology and scope of the problem. (2015) (171)
- Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment (2014) (162)
- North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. (2019) (154)
- Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization – systematic review and recommendations from the HS ALLIANCE working group (2018) (153)
- Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. (2008) (153)
- Risks of developing psychiatric disorders in pediatric patients with psoriasis. (2012) (152)
- Risk factors associated with striae gravidarum. (2004) (145)
- The dermatology workforce shortage. (2004) (141)
- Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. (2013) (139)
- Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. (2012) (137)
- Comparison of the epidemiology of acne vulgaris among Caucasian, Asian, Continental Indian and African American women (2011) (133)
- Topical vitamins, minerals and botanical ingredients as modulators of environmental and chronological skin damage (2003) (132)
- HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled portion of a phase 2 adalimumab study (2015) (126)
- Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. (2012) (122)
- Conditioned Pharmacotherapeutic Effects: A Preliminary Study (2010) (122)
- The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study (2011) (122)
- Systemic associations of hidradenitis suppurativa. (2015) (120)
- From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. (2008) (120)
- Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis. Implications for diagnosis and therapy. (2000) (119)
- Hidradenitis suppurativa (1987) (119)
- Long‐term efficacy of ustekinumab in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 1 trial through up to 3 years (2012) (119)
- Double-blinded, placebo-controlled trial of green tea extracts in the clinical and histologic appearance of photoaging skin. (2006) (118)
- Economic burden of comorbidities in patients with psoriasis is substantial (2011) (115)
- Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. (2012) (109)
- Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR)* (2014) (109)
- Pregnancy Outcomes After Exposure to Certolizumab Pegol (2018) (107)
- Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis. (2010) (104)
- The Impact of Administrative Burden on Academic Physicians: Results of a Hospital-Wide Physician Survey (2017) (104)
- Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis (2016) (104)
- Acne vulgaris in women: prevalence across the life span. (2012) (103)
- Review of treatment options for psoriasis in pregnant or lactating women: from the Medical Board of the National Psoriasis Foundation. (2012) (102)
- The burden of autoimmune disease: a comparison of prevalence ratios in patients with psoriatic arthritis and psoriasis. (2009) (102)
- Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001–2002 (2006) (102)
- Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased (2004) (99)
- Impact of adalimumab treatment on patient‐reported outcomes: Results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis (2007) (96)
- Psoriasis epidemiology: the interplay of genes and the environment. (2013) (92)
- Who else is providing care in dermatology practices? Trends in the use of nonphysician clinicians. (2008) (85)
- Epidemiology & Health Services Research (2010) (84)
- Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial. (2005) (81)
- Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR) (2018) (79)
- Re-Categorization of Psoriasis Severity: Delphi Consensus from the International Psoriasis Council. (2019) (76)
- Cutaneous effects of BRAF inhibitor therapy: a case series. (2013) (75)
- Pediatric Psoriasis Comorbidity Screening Guidelines (2017) (75)
- A Single‐Blinded, Randomized, Controlled Clinical Trial Evaluating the Effect of Face Washing on Acne Vulgaris (2006) (74)
- The impact of psoriasis on pregnancy outcomes. (2012) (74)
- Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). (2016) (73)
- Update on biologic safety for patients with psoriasis during pregnancy (2017) (73)
- Counter-regulatory balance: atopic dermatitis in patients undergoing infliximab infusion therapy. (2004) (72)
- Psychometric properties of the Itch Numeric Rating Scale in patients with moderate‐to‐severe plaque psoriasis (2016) (70)
- Psoriasis and Cardiovascular Disease. (2015) (69)
- Association of hidradenitis suppurativa disease severity with increased risk for systemic comorbidities (2014) (69)
- Increased diagnosis of thin superficial spreading melanomas: A 20-year study. (2012) (68)
- The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis. (2012) (68)
- Accumulating evidence for the association and shared pathogenic mechanisms between psoriasis and cardiovascular-related comorbidities. (2014) (65)
- The Handicap of Hidradenitis Suppurativa. (2016) (65)
- Clinical and immunologic assessment of patients with psoriasis in a randomized, double-blind, placebo-controlled trial using recombinant human interleukin 10. (2002) (65)
- OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results. (2015) (63)
- Pregnancy Outcomes After Exposure to Certolizumab Pegol Updated Results From a Pharmacovigilance Safety Database (2018) (61)
- Maintenance of clinical response and consistent safety profile with up to three years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials. (2019) (61)
- Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment. (2008) (60)
- What causes hidradenitis suppurativa ?—15 years after (2020) (60)
- Generational differences in practice patterns of dermatologists in the United States: implications for workforce planning. (2004) (59)
- Accessibility to air travel correlates strongly with increasing melanoma incidence* (2006) (59)
- Using the Physician Global Assessment in a clinical setting to measure and track patient outcomes. (2015) (58)
- Latitude and psoriasis prevalence. (2011) (58)
- Clinical Goals and Barriers to Effective Psoriasis Care (2018) (58)
- Prevalence and Risk of Inflammatory Bowel Disease in Patients with Hidradenitis Suppurativa. (2017) (57)
- Medication formulation affects quality of life: a randomized single-blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis. (2003) (56)
- Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations (2021) (55)
- Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis: results from a randomized controlled trial (2014) (54)
- Challenges facing academic dermatology: survey data on the faculty workforce. (2006) (54)
- Psoriasis and psoriatic arthritis: separate or one and the same? (2007) (53)
- Meta-analysis comparing efficacy of benzoyl peroxide, clindamycin, benzoyl peroxide with salicylic acid, and combination benzoyl peroxide/clindamycin in acne. (2010) (53)
- Few Medicaid and uninsured patients are accessing dermatologists. (2006) (53)
- Meta-analysis comparing efficacy of antibiotics versus oral contraceptives in acne vulgaris. (2014) (50)
- Efficacy and Safety of Adalimumab among Patients with Moderate to Severe Psoriasis with Co-Morbidities (2011) (49)
- Longer-term impact of cardiology e-consults. (2016) (49)
- Safety of guselkumab in patients with moderate‐to‐severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies (2019) (48)
- Long‐term safety profile of ixekizumab in patients with moderate‐to‐severe plaque psoriasis: an integrated analysis from 11 clinical trials (2018) (47)
- Safety of tildrakizumab for moderate‐to‐severe plaque psoriasis: pooled analysis of three randomized controlled trials (2018) (47)
- Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005–09 (2014) (47)
- Self‐Reported Acne Severity, Treatment, and Belief Patterns across Multiple Racial and Ethnic Groups in Adolescent Students (2010) (45)
- Pregnancy outcomes in psoriasis: why do we know so little? (2009) (45)
- The Comorbidity Burden of Hidradenitis Suppurativa in the United States: A Claims Data Analysis (2018) (45)
- Clobetasol propionate emulsion formulation foam 0.05%: review of phase II open-label and phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents. (2008) (45)
- Antiandrogen therapy with spironolactone for the treatment of hidradenitis suppurativa (2019) (45)
- Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory (2014) (44)
- Striae and pelvic relaxation: two disorders of connective tissue with a strong association. (2006) (44)
- US dermatology residents' satisfaction with training and mentoring: survey results from the 2005 and 2006 Las Vegas Dermatology Seminars. (2008) (44)
- Cardiovascular disease and classic cardiovascular risk factors in patients with psoriasis (2009) (43)
- Age‐induced and photoinduced changes in gene expression profiles in facial skin of Caucasian females across 6 decades of age (2018) (43)
- Management of Hidradenitis Suppurativa Wounds with an Internal Vacuum-Assisted Closure Device (2014) (43)
- Reduction in the appearance of facial hyperpigmentation after use of moisturizers with a combination of topical niacinamide and N‐acetyl glucosamine: results of a randomized, double‐blind, vehicle‐controlled trial (2010) (42)
- Gender and parenting significantly affect work hours of recent dermatology program graduates. (2004) (42)
- Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States. (2016) (41)
- Assessing the role of race in quantitative measures of skin pigmentation and clinical assessments of photosensitivity. (2004) (39)
- Cutaneous manifestations of thyroid disease. (2008) (39)
- A survey assessment of the recognition and treatment of psychocutaneous disorders in the outpatient dermatology setting: how prepared are we? (2013) (38)
- Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years. (2018) (37)
- Targeted Reminder Phone Calls to Patients at High Risk of No-Show for Primary Care Appointment: A Randomized Trial (2016) (37)
- Impact of Endometriosis on Life-Course Potential: A Narrative Review (2021) (37)
- Seasonal variation of acne and psoriasis: A 3-year study using the Physician Global Assessment severity scale. (2015) (37)
- A single-center, randomized double-blind, parallel-group study to examine the safety and efficacy of 3mg drospirenone/0.02 mg ethinyl estradiol compared with placebo in the treatment of moderate truncal acne vulgaris. (2013) (37)
- The validity of the diagnostic code for hidradenitis suppurativa in an electronic database (2014) (37)
- Psoriasis prevalence among the 2009 AAD National Melanoma/Skin Cancer Screening Program participants (2013) (36)
- Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials. (2016) (36)
- Cumulative life course impairment: evidence for psoriasis. (2013) (36)
- Current guidelines for psoriasis treatment: a work in progress. (2018) (35)
- Eruptive xanthomas associated with olanzapine use. (2003) (34)
- A multivariate analysis of dermatology missed appointment predictors. (2013) (34)
- OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasis. (2013) (34)
- A pilot study of etanercept treatment for pemphigus vulgaris. (2010) (34)
- Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient‐reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials (2016) (33)
- Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States (2015) (33)
- Health disparities among different ethnic and racial middle and high school students in sun exposure beliefs and knowledge. (2010) (33)
- Dermatology: a unique case of specialty workforce economics. (2003) (33)
- Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severity (2013) (33)
- Metronidazole in the treatment of rosacea: do formulation, dosing, and concentration matter? (2006) (32)
- Fate of manuscripts declined by the Journal of the American Academy of Dermatology. (2008) (31)
- Psoriasis and the life cycle of persistent life effects. (2015) (31)
- Controlled nail trephination for subungual hematoma. (2006) (31)
- Disease burden and cost of hidradenitis suppurativa: a retrospective examination of US administrative claims data (2019) (31)
- Adalimumab medium‐term dosing strategy in moderate‐to‐severe hidradenitis suppurativa: integrated results from the phase III randomized placebo‐controlled PIONEER trials (2019) (30)
- Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients (2020) (30)
- Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial. (2011) (29)
- Quality of Life and Treatment Satisfaction among Patients with Psoriasis and Psoriatic Arthritis and Patients with Psoriasis Only (2008) (29)
- Alefacept for erosive lichen planus: a case series. (2008) (28)
- Diffuse morbilliform eruption after consumption of ginkgo biloba supplement. (2002) (28)
- Skin carotenoid levels in adult patients with psoriasis (2011) (28)
- Effects of moisturization on epidermal homeostasis and differentiation (2006) (28)
- Development and initial psychometric evaluation of patient-reported outcome questionnaires to evaluate the symptoms and impact of hidradenitis suppurativa (2018) (27)
- Efficacy of a jellyfish sting inhibitor in preventing jellyfish stings in normal volunteers. (2004) (27)
- Comorbidities of hidradenitis suppurativa (2017) (26)
- Reductions in healthcare resource utilization in psoriatic arthritis patients receiving etanercept therapy: results from the educate trial. (2007) (26)
- Counterpoint: analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. (2013) (25)
- Psoriasis patients’ willingness to accept side-effect risks for improved treatment efficacy (2015) (25)
- TNF-α inhibitors in the treatment of hidradenitis suppurativa (2019) (25)
- New antifungal therapies for the treatment of onychomycosis. (2009) (24)
- A randomized controlled clinical trial assessing the effect of betamethasone valerate 0.12% foam on the short-term treatment of stasis dermatitis. (2005) (24)
- Effect of Age at Diagnosis on Chronic Quality of Life and Long‐Term Outcomes of Individuals with Psoriasis (2015) (24)
- Clobetasol propionate foam in the treatment of psoriasis (2005) (24)
- Beyond the blot: cutting edge tools for genomics, proteomics and metabolomics analyses and previous successes (2012) (24)
- New antifungal therapies for the treatment of onychomycosis (2009) (24)
- Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis (2017) (23)
- Understanding the Relationship Between Pruritus Severity and Work Productivity in Patients With Moderate-to-Severe Psoriasis: Sleep Problems Are a Mediating Factor. (2016) (23)
- Acne and oral contraceptives: update on women's health screening guidelines. (2008) (23)
- Adverse Reactions to Biologics in Psoriasis. (2018) (22)
- Meta-analysis of randomized controlled trials using 5% benzoyl peroxide and clindamycin versus 2.5% benzoyl peroxide and clindamycin topical treatments in acne. (2011) (22)
- Treatments for mild-to-moderate recalcitrant plaque psoriasis: expected clinical and economic outcomes for first-line and second-line care. (2005) (22)
- Efficacy and safety of ixekizumab over 4 years of open‐label treatment in a phase 2 study in chronic plaque psoriasis (2018) (21)
- Briakinumab (2009) (21)
- Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab† (2019) (20)
- Psoriasis and herpes simplex virus are highly stigmatizing compared with other common dermatologic conditions: A survey-based study. (2015) (20)
- Efficacy of tildrakizumab for moderate‐to‐severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28 (2019) (20)
- Geographic distribution of clinical trials may lead to inequities in access (2014) (20)
- Adalimumab alleviates skin pain in patients with moderate‐to‐severe hidradenitis suppurativa: Secondary efficacy results from the PIONEER I and PIONEER II randomized controlled trials (2018) (20)
- Systemic causes of hair loss (2016) (19)
- Patient‐reported symptoms and signs of moderate‐to‐severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial (2018) (19)
- Text-message reminders to improve sunscreen use. (2009) (19)
- Weight loss in obese patients with psoriasis can be successfully achieved during a course of phototherapy (2011) (19)
- Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension. (2018) (18)
- The dermatology life quality index (DLQI) provides qualitatively different information from the pasi (2004) (18)
- Pregnancy Outcomes in Women With Moderate-to-Severe Psoriasis From the Psoriasis Longitudinal Assessment and Registry (PSOLAR) (2021) (18)
- Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies† (2019) (18)
- A novel approach to administration of peptides in women: Systemic absorption of a GnRH agonist via transvaginal ring delivery system. (2016) (18)
- A randomized, double-blind, placebo-controlled, pilot study to assess the efficacy and safety of clindamycin 1.2% and tretinoin 0.025% combination gel for the treatment of acne rosacea over 12 weeks. (2012) (18)
- Time for a change? Updated guidelines using interferon gamma release assays for detection of latent tuberculosis infection in the office setting. (2012) (17)
- Getting under the Skin: Report from the International Psoriasis Council Workshop on the Role of Stress in Psoriasis (2016) (17)
- Su1799 - Pregnancy Outcomes in Women Exposed to Ustekinumab (2018) (17)
- Long‐term safety of biologics in dermatology (2009) (17)
- Quality of life considerations in psoriasis treatment. (2003) (16)
- A measure of chronic quality of life predicts socioeconomic and medical outcomes in psoriasis patients (2015) (16)
- Psoriasis - The Life Course Approach. (2016) (16)
- An assessment of the relative impact of hidradenitis suppurativa, psoriasis, and obesity on quality of life☆☆☆ (2018) (16)
- The relative impact of psoriasis and obesity on socioeconomic and medical outcomes in psoriasis patients (2014) (16)
- Chronic pain management in dermatology: a guide to assessment and nonopioid pharmacotherapy. (2015) (15)
- Health disparities in arthritis and musculoskeletal and skin diseases-the dermatology session: National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, December 15-16, 2000. (2002) (15)
- Achieving Hidradenitis Suppurativa Response Score is Associated with Significant Improvement in Clinical and Patient-reported Outcomes: Post Hoc Analysis of Pooled Data From PIONEER I and II. (2018) (15)
- Risk of COVID-19 in dermatologic patients receiving long-term immunomodulatory therapy (2020) (14)
- Socioeconomic disability in psoriasis (2009) (14)
- Chronic pain management in dermatology: pharmacotherapy and therapeutic monitoring with opioid analgesia. (2015) (14)
- How Low Should You Go: Novel Device for Nail Trephination (2006) (14)
- Workforce Characteristics of Mohs Surgery Fellows (2004) (14)
- Psoriasis and Mental Health Workshop Report: Exploring the Links between Psychosocial Factors, Psoriasis, Neuroinflammation and Cardiovascular Disease Risk (2019) (14)
- Recent Changes in the Workforce and Practice of Dermatologic Surgery (2009) (13)
- Reporting of ethical review of clinical research submitted to the Journal of the American Academy of Dermatology. (2007) (13)
- Reliability of the hidradenitis suppurativa clinical response in the assessment of patients with hidradenitis suppurativa (2018) (13)
- Efficacy and Tolerability of a Cosmetically Acceptable Coal Tar Solution in the Treatment of Moderate Plaque Psoriasis (2010) (13)
- Skin sun-acne tutorial evaluation among middle- and high-school students in central New Jersey. (2007) (13)
- TARGETING IL-23: INSIGHTS INTO THE PATHOGENESIS AND THE TREATMENT OF PSORIASIS (2010) (13)
- Itch intensity in moderate‐to‐severe plaque psoriasis versus atopic dermatitis: A meta‐analysis (2017) (13)
- Telehealth use by age and race at a single academic medical center during COVID-19. (2021) (13)
- Success of automated algorithmic scheduling in an outpatient setting. (2014) (13)
- Hidradenitis suppurativa: current progress and future questions. (2014) (12)
- Biologicals in the treatment of psoriasis. (2007) (12)
- Rising educational debt levels in recent dermatology trainees and effects on career choices. (2006) (12)
- Skin differences, needs, and disorders across global populations. (2008) (12)
- Correlation of psoriasis activity with socioeconomic status: cross‐sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR) (2018) (12)
- Baseline patient‐reported outcomes from UNITE: an observational, international, multicentre registry to evaluate hidradenitis suppurativa in clinical practice (2019) (12)
- Publication trends in hidradenitis suppurativa from 2008 to 2018 (2020) (12)
- A critical assessment of composite and coprimary endpoints: a complex problem. (2008) (12)
- The temporal association between cutaneous T‐cell lymphoma and psoriasis: implications for common biologic processes (2016) (12)
- Genetic basis for skin youthfulness. (2019) (12)
- Teaching empathy to undergraduate medical students using a temporary tattoo simulating psoriasis. (2012) (12)
- Managing the dose escalation of biologics in an era of cost containment: the need for a rational strategy☆☆☆ (2016) (12)
- A Single‐Blinded, Randomized Pilot Study to Evaluate the Effect of Exercise‐Induced Sweat on Truncal Acne (2008) (12)
- Melanoma in Hong Kong between 1983 and 2002: a decreasing trend in incidence observed in a complex socio–political and economic setting (2010) (12)
- Survey research in dermatology: guidelines for success. (2009) (11)
- Metabolic dysfunction in human skin: Restoration of mitochondrial integrity and metabolic output by nicotinamide (niacinamide) in primary dermal fibroblasts from older aged donors (2020) (11)
- Baseline Characteristics from UNITE: An Observational, International, Multicentre Registry to Evaluate Hidradenitis Suppurativa (Acne Inversa) in Clinical Practice (2020) (11)
- Overview and update on biologic therapy for moderate-to-severe hidradenitis suppurativa (2018) (11)
- Dermatological diseases and cumulative life course impairment (2013) (11)
- Cytarabine-induced acute generalized exanthematous pustulosis. (2002) (11)
- Biologic Treatment for Hidradenitis Suppurativa (2019) (11)
- Clobetasol propionate emollient formulation foam in the treatment of corticosteroid-responsive dermatoses. (2008) (10)
- An Assessment of the Cost-Utility of Therapy for Psoriasis (2006) (10)
- Future perspectives/quo vadis psoriasis treatment? Immunology, pharmacogenomics, and epidemiology. (2008) (10)
- Should We Leave the Skin Biopsies to the Dermatologists? (2016) (10)
- Aging Associated Changes in the Adult Human Skin Microbiome and the Host Factors That Affect Skin Microbiome Composition. (2021) (10)
- Predictions, Surprises, and the Future of the Dermatology Workforce. (2018) (9)
- Sex, academics, and dermatology leadership: progress made, but no more excuses. (2012) (9)
- Biologic therapies for the treatment of hidradenitis suppurativa (2020) (9)
- AB0912 Two-year efficacy and safety of guselkumab for treatment of moderate-to-severe psoriasis: phase 3 voyage 1 trial (2018) (9)
- Response to: Remission of hidradenitis suppurativa after bariatric surgery (2018) (9)
- Assessing the Impact of Improvements in PASI and Itch Scores on Patients' Quality of Life in the Treatment of Psoriasis. (2019) (9)
- Pyrithione zinc as a general management strategy for hidradenitis suppurativa. (2015) (9)
- Delivering value in dermatology: insights from skin cancer detection in routine clinical visits. (2015) (9)
- Telehealth Use by Age and Race at a Single Academic Medical Center During the COVID-19 Pandemic: Retrospective Cohort Study (2021) (8)
- Examining the prior authorization process, patient outcomes, and the impact of a pharmacy intervention: A single-center review. (2019) (8)
- Methotrexate shows benefit in a subset of patients with severe hidradenitis suppurativa (2020) (8)
- Clobetasol propionate emollient formulation foam in the treatment of corticosteroid-responsive dermatoses (2008) (8)
- Psoriasis severity: commonly used clinical thresholds may not adequately convey patient impact (2020) (7)
- Investigating race and gender in age at onset of hidradenitis suppurativa (2019) (7)
- Medical versus surgical dermatology: how much training do residents receive? (2006) (7)
- Understanding the cost of dermatologic care: A survey study of dermatology providers, residents, and patients (2017) (7)
- Women in leadership positions within obstetrics and gynecology: does the past explain the present? (2013) (7)
- Immunotherapy of Recurrent Herpes Labialis With Squaric Acid (2017) (7)
- Engaging patients to decrease costs and improve outcomes. (2015) (7)
- Clinically meaningful improvements in health-related quality of life from etanercept therapy for patients with moderate to severe psoriasis (2004) (7)
- Leadership workforce in academic dermatology. (2007) (7)
- The canary seems fine: the effects of the economy on job-seeking experiences of recent dermatology training program graduates. (2010) (7)
- The spectrum of nephrocutaneous diseases and associations: Inflammatory and medication-related nephrocutaneous associations. (2016) (6)
- Clinical Presentation of Hidradenitis Suppurativa (2017) (6)
- Overview and update on biologic therapy for moderate-to-severe hidradenitis suppurativa. (2018) (6)
- Face time versus test ordering: is there a trade-off? (2012) (6)
- Residency applications and identification of factors associated with residents' ultimate career decisions. (2009) (6)
- Cutaneous effects of BRAF inhibitor therapy: a case series. (2013) (6)
- A Survey of Dermatology Nurse Practitioners: Work Setting, Training, and Job Satisfaction (2010) (6)
- A double-blinded, randomized, controlled trial to quantitate photoprotective effects of an antioxidant combination product. (2012) (6)
- Treatment Satisfaction and Health-related Quality of Life among Individuals with Psoriasis: National Psoriasis Foundation Survey Findings (2008) (6)
- Hidradenitis suppurativa scoring systems: can we choose just one? (2017) (6)
- Patient-clinician concordance, face-time and access. (2014) (6)
- Survey on Clinician Perceptions and Practices Regarding Goals of Care Conversations. (2016) (6)
- Median dermatology base incomes in senior academia and practice are comparable, but a significant income gap exists at junior levels. (2006) (6)
- Online communications among hidradenitis suppurativa patients reflect community needs. (2018) (6)
- Proceeding report of the Symposium on Hidradenitis Suppurativa Advances (SHSA) (2018) (6)
- Re. major life‐changing decisions and cumulative life course impairment (2011) (6)
- Unmet clinical needs and burden of disease in hidradenitis suppurativa: real‐world experience from EU5 and US (2022) (5)
- Practice Models and Roles of Physician Extenders in Dermatologic Surgery (2011) (5)
- Performing research in pregnancy: Challenges and perspectives. (2016) (5)
- The relative popularity of nonprocedural dermatology fellowships. (2012) (5)
- There's no place like home: an analysis of migration patterns of dermatology residents prior to, during, and after their training. (2016) (5)
- Specializing in accountability: strategies to prepare a subspecialty workforce for care delivery redesign. (2013) (5)
- IL‐17A is a pertinent therapeutic target for moderate‐to‐severe hidradenitis suppurativa: Combined results from a pre‐clinical and phase II proof‐of‐concept study (2022) (5)
- The spectrum of nephrocutaneous diseases and associations: Genetic causes of nephrocutaneous disease. (2016) (5)
- Assessment of incentives for student loan debt repayment among recent dermatology residency graduates. (2009) (5)
- Dermatology's Researchers of the Future: Our Workforce Pipeline and Richest Opportunities. (2016) (5)
- Academia and the Millennials: Trending Career Choices of Graduating Dermatology Residents 1999-2012. (2015) (5)
- Career Trajectory and Job Satisfaction Trends in Mohs Micrographic Surgeons (2011) (5)
- Dermatology urgent care: enlisting help from primary care in triage decisions. (2014) (5)
- Practice patterns among osteopathic dermatologists in the United States. (2007) (5)
- Plastic Surgical Management of Hidradenitis Suppurativa (2021) (5)
- Acne Knowledge of Hispanic Parents of Teenagers with Mild to Moderate Acne (2016) (4)
- Treatment Outcomes Associated With Dupilumab Use in Patients With Atopic Dermatitis: 1-Year Results From the RELIEVE-AD Study. (2021) (4)
- Remission of psoriasis 13 years after autologous stem cell transplant. (2015) (4)
- OBSERVE-5, an Observational Post-Marketing Safety Surveillance Registry of Etanercept for the Treatment of Psoriasis: A Model for Studying New Psoriasis Therapies (2010) (4)
- Career satisfaction of leaders in academic dermatology: Results from a national survey,☆ (2019) (4)
- A visit guide for hidradenitis suppurativa - managing a complex disease in a busy clinic. (2020) (4)
- Use of biologics in pregnancy: limitations stemming from clinical trials and registry experience (2019) (4)
- Academic Productivity and Affiliation of Dermatologic Surgeons (2009) (4)
- 15036 Pregnancy outcomes in women exposed to guselkumab: Experience from the clinical development program (2020) (4)
- Yin and Yang of skin microbiota in “swimmer acne” (2022) (4)
- Increased Prevalence of Cancer in Adult Patients With Psoriasis in the United States: A Claims Based Analysis. (2018) (4)
- Mandatory registration of clinical trials: a major step forward for evidence-based medicine. (2005) (4)
- Efficacy and safety of mirikizumab in psoriasis: results from a 52‐week, double‐blind, placebo‐controlled, randomized withdrawal, phase III trial (OASIS‐1) (2022) (4)
- Expanding scope of dermatologic mid-level practitioners includes prescription of complex medication. (2015) (3)
- Dinners with Irwin: mentorship, the work force, and the future of academic dermatology. (2006) (3)
- A cost-effectiveness comparison of liquor carbonis distillate solution and calcipotriol cream in the treatment of moderate chronic plaque psoriasis. (2010) (3)
- Real-time location systems, normative messaging and modifying clinician behavior: a pilot study (2014) (3)
- Effect of tildrakizumab on personal relationships in patients with moderate-to-severe chronic plaque psoriasis (2018) (3)
- Pharmacoeconomics of Systemic and Biologic Therapy in Dermatology (2018) (3)
- A Strategic Approach to Setting the Research Agenda in Psoriasis (2011) (3)
- Hidradenitis suppurativa for the dermatologic hospitalist. (2019) (3)
- Reply to : “ An exploratory study using framework analysis to investigate health-seeking behaviour in patients with psoriasis ” (3)
- Effects of TNF‐alpha antagonism in patients with metabolic syndrome and psoriasis (2015) (3)
- Advances in the treatment of acne. (2008) (3)
- Ketoconazole 2% foam for treatment of seborrheic dermatitis (2008) (3)
- 346 Addressing the under-treatment of patients with psoriasis - Preliminary survey results (2017) (3)
- Pregnancy outcomes in patients with psoriasis, psoriatic arthritis, or axial spondyloarthritis receiving ixekizumab (2021) (3)
- Burnout Among All Groups of Physicians-Mitigation Strategies for Dermatologists. (2020) (3)
- Workforce characteristics of dermatology nurse practitioners. (2009) (3)
- Mycosis fungoides and serology for human T-cell lymphotropic virus, type 1. (2002) (3)
- Psoriasis and cardiovascular disease: another contribution in the hierarchy of evidence (2012) (3)
- Hidradenitis suppurativa disease course during pregnancy and postpartum: a retrospective survey study (2021) (2)
- Impact of childhood atopic dermatitis on life decisions for caregivers and families (2022) (2)
- Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials (2023) (2)
- Green Tea Extract (2013) (2)
- Observations from our evaluation of bodyweight changes after initiation of a biologic therapy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR) (2017) (2)
- Validating standardized acquisition of digital dermatologic images for use in the national health and nutrition examination survey. (2006) (2)
- Rethinking eligibility creep. (2008) (2)
- Only skin deep: optimism and public self-consciousness did not associate with the placebo response in a dermatology clinical trial. (2014) (2)
- An evaluation of educational debt levels in dermatology residents and effects on career choices. (2014) (2)
- Correspondence: Assessing dermatology board examination competence using questions distribution: a 12‐year Brazilian experience (2010) (2)
- Single blind, randomized, controlled trial of a lightening product with and without iontophoresis versus tretinoin and vehicle for hyperpigmentation. (2015) (2)
- A double-blind comparison of the efficacy of a salicylic acid based acne treatment regimen versus a benzoyl peroxide based acne treatment regimen for the treatment of acne vulgaris (2004) (2)
- PSY6 USTEKINUMAB IS ASSOCIATED WITH SIGNIFICANT IMPROVEMENTS IN OVERALL HEALTH-RELATED QUALITY OF LIFE IN MODERATE-TO-SEVERE PSORIASIS PATIENTS (2009) (2)
- Challenges for dermatologists during the COVID-19 pandemic: A qualitative study (2022) (2)
- Immunogenicity with tildrakizumab, an anti–IL-23p19 monoclonal antibody, in a pooled analysis of three randomized controlled trials in patients with chronic plaque psoriasis (2018) (2)
- Psoriasis and latitude: Analytic approaches and future data needs. (2017) (2)
- Targeting the IL-12/IL-23 cytokine family in the treatment of psoriatic disease (2008) (2)
- Treatment of Hidradenitis Suppurativa (2017) (2)
- Transcriptomic analysis of human skin wound healing and rejuvenation following ablative fractional laser treatment (2021) (2)
- A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs (2021) (2)
- Psoriasis: Knowledge, Attitudes and Perceptions among Primary Care Providers. (2020) (2)
- Research integrity in the modern era: current gaps in our knowledge and thinking (2014) (2)
- Assessment of treatment‐seeking behaviour in patients with psoriasis (2018) (2)
- 430 Crohn's disease prevalence prior to and following hidradenitis suppurativa diagnosis (2020) (1)
- Rethinking the PASI: variations on a theme 1 1 Disclosure not available at press time. (2004) (1)
- Advances in biologic and small molecule therapies for hidradenitis suppurativa (2022) (1)
- 27035 Assessment of the natural history of hidradenitis suppurativa (HS) over 4 years: Results from the HS UNITE registry (2021) (1)
- Discordance Between Patient Reported Motivations to Seek Treatment for Psoriasis Compared to Television Advertisements. (2018) (1)
- Information disclosure and the Physician Payments Sunshine Act. (2011) (1)
- Measuring Disease specific impact and symptoms among patients with Hidradenitis Suppurativa (2015) (1)
- 100 Questions & Answers About Psoriasis (2004) (1)
- TeleConnect: digitally connecting physicians across the health care system. (2021) (1)
- 34658 Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe plaque psoriasis who had inadequate responses to apremilast at week 24 in the phase 3 POETYK PSO-1 and PSO-2 trials (2022) (1)
- 25665 Efficacy and safety of mirikizumab in psoriasis: 52-week results from the OASIS-1 randomized controlled trial (2021) (1)
- 184 Prevalence of hidradenitis suppurativa stratified by age and sex (2019) (1)
- Prevalence of skin disorders in patients seeking health care. (2013) (1)
- Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial (2023) (1)
- Systemic Therapies for Acne (2014) (1)
- Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial. (2022) (1)
- Dermatologic workforce on the Texas border: using burden on primary care as an outcome measure (2013) (1)
- Safety and tolerability of tildrakizumab, an anti–interleukin-23p19 monoclonal antibody, in patients with chronic plaque psoriasis over two years of treatment: Results from long-term extensions of two phase III clinical studies (reSURFACE 1 and reSURFACE 2) (2018) (1)
- Patient preferences for dermatology visits. (2009) (1)
- Early onset of senescence and imbalanced epidermal homeostasis across the decades in photoexposed human skin: Fingerprints of inflammaging (2022) (1)
- A new era in skin care: the omics revolution (2012) (1)
- Skin carotenoid levels are not associated with risk of nonmelanoma skin cancer: response to "Supplement use and the risk of cutaneous squamous cell carcinoma". (2012) (1)
- A double-blinded, placebo-controlled trial to determine the role of a combination regimen of systemic and topical green tea in UV protection and the improvement of skin appearance (2001) (1)
- An Open-Label, Prospective, Pilot Study of Hypertonic Saline for Hidradenitis Suppurativa (2022) (1)
- 10th European Hidradenitis Suppurativa (EHSF) e.V. Conference. (2021) (1)
- Treatment of Moderate to Severe Hidradenitis Suppurativa (2013) (1)
- How many people develop anti‐drug antibodies to the biologic drug tildrakizumab, and what impact does this have on the effectiveness of their treatment (2020) (1)
- High placebo rates in clinical trials: is the problem scoring systems or drug efficacy? (2020) (1)
- Real-World Findings on the Characteristics and Treatment Exposures of Patients with Hidradenitis Suppurativa from US Claims Data (2022) (1)
- Yale University School of Medicine Thesis Abstracts — 2009 (2009) (0)
- An assessment of the relative impact of skin disease on quality of life in patients with hidradenitis suppurativa versus psoriasis (2018) (0)
- Effects of swimming on facial sebum in adolescents (2021) (0)
- Acknowledgement to Referees (2016) (0)
- Continuous Weekly Adalimumab is the Optimal Long-Term Strategy for Patients with Moderate-to-Severe Hidradenitis Suppurativa: Results from the PIONEER Open Label Extension Trial (2017) (0)
- Incorrect Subcategory in a Table and Revision for Text. (2016) (0)
- 681 Clinical trials in hidradenitis suppurativa and psoriasis under-represent certain gender, ethnic, and racial groups (2022) (0)
- Books Received (2013) (0)
- Psoriasis, a proof-of-principle condition for immune-mediated inflammatory disorders: perspectives toward optimal clinical trial design (2012) (0)
- 595 Opinions and practices of primary care physicians managing psoriasis (2019) (0)
- Cost-effectiveness of the new biologic modifiers for therapy of psoriasis (2004) (0)
- Teachable Action for Leaders Committed to Improving Physician Work Life: Continuing Education. (2015) (0)
- 569 The patient perspective on psoriasis disease remission (2018) (0)
- Treatment of Psoriasis in Pregnancy (2020) (0)
- Clinical presentation of psoriasis and psoriatic arthritis (2016) (0)
- A Successful Pilot to Improve Access by Adjusting Discharge andFollow-Up Rates (2018) (0)
- Impact of the COVID-19 Pandemic on the Delivery of Dermatological Care (2022) (0)
- A study of the drug tildrakizumab for plaque psoriasis (2020) (0)
- Innovative care, medical research, and the ethics of informed consent. (2007) (0)
- M204 CLINICAL PRESENTATION AND DIAGNOSIS OF HIDRADENITIS SUPPURATIVA (2012) (0)
- PLACEBO RESPONSE? Authors' reply (2010) (0)
- Erythrocyte sedimentation rate, rather than C-reactive protein, may be the preferred biomarker for hidradenitis suppurativa (2022) (0)
- 16971 Self-reported patient-perceived barriers to care in psoriasis treatment (2020) (0)
- Response to Letter to the Editor entitled: Rethinking biologic and pregnancy research: The importance of assessing postpartum immunosuppression of the infant (2021) (0)
- PIONEER I: Adalimumab Provides Benefit in Hidradenitis Suppurativa (2015) (0)
- Abstract 868: Prevalence, Underdiagnosis, and Undertreatment of Cardiovascular Risk Factors in Patients With Moderate-to-Severe Psoriasis (2009) (0)
- A Closer Inspection of the Number Needed to Biopsy-Reply. (2016) (0)
- Academic? Authors' reply (2006) (0)
- Safety of tildrakizumab for moderate-to-severe chronic plaque psoriasis: Pooled analysis of three randomized controlled studies (2018) (0)
- 15592 Psoriasis by body region: Does site predict recurrence? (2020) (0)
- Guselkumab 在接受 100 周治疗的银屑病患者中的安全性 (2019) (0)
- Multiethnic comparison of facial skin aging (2018) (0)
- Travel burden on patients at a subspecialty hidradenitis suppurativa clinic: a single-center retrospective study (2022) (0)
- Quantifying Itch: Measurement on the Way to Management. (2021) (0)
- Experience With Anti – TNF-α Therapy in Dermatologic Immune-Mediated Inflammatory Disorders 3 Psoriasis : Evidence for the Efficacy and Safety of Anti – TNF-α Treatment (2004) (0)
- The Management of Women with Chronic Immune Disorders in the Era of Biologics: Caveats from Other Specialties (2011) (0)
- Treatment of hidradenitis suppurativa resolves associated hematologic abnormalities (2022) (0)
- 445 Diagnostic delay in hidradenitis suppurativa not associated with severity (2020) (0)
- Safety of guselkumab in patients with psoriasis treated through 100 weeks (2019) (0)
- Expectations for AI in Healthcare Become More Modest (2021) (0)
- Infection rates in the ustekinumab psoriasis clinical trial program: Update with up to 4 years of follow-up (2012) (0)
- Inflammaging in human photoexposed skin: Early onset of senescence and imbalanced epidermal homeostasis across the decades (2022) (0)
- Marked long-term clinical response to treatment with ustekinumab, a new monoclonal antibody for the treatment of psoriasis (2008) (0)
- The recent economic downturn has had no effect on recently-graduated dermatologists’ workforce choices 1 ☆ (2004) (0)
- LB901 Inflammaging in human skin: Early onset of senescence and imbalanced epidermal homeostasis across the decades (2022) (0)
- Dermatologic inflammatory conditions require high loading and maintenance doses of biologic therapy (2022) (0)
- 212 Patient characteristics in commercial and Medicaid patients with hidradenitis suppurativa (2017) (0)
- Surgical Management of Hidradenitis Suppurativa: A Two-Center Retrospective Study (2022) (0)
- Inflammatory nephrocutaneous diseases including associated cutaneous and renal manifestations and referral considerations Disease Cutaneous findings Renal findings (2016) (0)
- Merging COVID19 virtual hospitals for the future (2020) (0)
- 16480 Characteristics associated with progression of hidradenitis suppurativa: 2-year interim results from the HS UNITE registry (2020) (0)
- 685 Evaluation of racial differences in prescription rates of systemic medications for psoriasis and psoriatic arthritis (2022) (0)
- Assessing the burden of psoriasis 1,2 (2004) (0)
- Treatment of psoriasis in pregnancy. (2020) (0)
- HiSCR (Hidradenitis Suppurativa Clinical Response) (2018) (0)
- 1134 Comparison of placebo response rates in failed vs successful phase 2/3 clinical trials in hidradenitis suppurativa and atopic dermatitis (2023) (0)
- 33631 A cost comparison of over the counter acne products available for “spot treatment” (2022) (0)
- When to Treat , How to Use : The Expanding Role of TNF-Antagonists in Dermatology Getting to the Cause : TNF-Antagonists in the Treatment of Psoriatic Disorders (2006) (0)
- 15322 Pregnancy outcomes in women with moderate to severe psoriasis in PSOLAR (2020) (0)
- 15277 Malignancy rates and comparisons to the general US population through 3 years of follow-up in guselkumab-treated patients with moderate to severe psoriasis from the VOYAGE 1 and 2 trials (2020) (0)
- Impact of Film ("My Skin's on Fire: Living With Psoriasis") on Medical Student Education in Dermatology (2009) (0)
- Etanercept reduces pruritus in patients with moderate to severe psoriasis (2004) (0)
- 13752 Geographic distribution of hidradenitis suppurativa publications may signal lack of diversity (2020) (0)
- The assessment of Fitzpatrick skin type using digital images (2003) (0)
- Dermatology Clinical Trials (2010) (0)
- THE PRACTICAL USE OF INFLIXIMAB IN THE OFFICE : AS-OBSERVED DATA FROM ONE DERMATOLOGIST ’ S EXPERIENCE (2007) (0)
- Refining how we measure as we test: new insights using adalimumab in patients with hidradenitis suppurativa (2021) (0)
- Newsletter No. 1 / 2008 (2008) (0)
- 490 Feasibility of examining fluorescence of follicular sebum and C. acnes after pool water immersion (2020) (0)
- 480 Differences in timing of prescriptions after FDA approval in psoriasis based on race (2023) (0)
- 543 Evaluating the burden of prior authorization in the treatment of psoriasis (2018) (0)
- Evaluation of Telehealth Visit Attendance After Implementation of a Patient Navigator Program (2022) (0)
- 423 Baseline C-reactive protein correlates with adalimumab and placebo 3non-response in patients with hidradenitis suppurativa (2023) (0)
- Skin and Anti-Aging Research Update: Proceedings from the 2007 World Congress of Dermatology (2008) (0)
- Hidradenitis Suppurativa Epidemiology (2022) (0)
- Post Marketing Safety Registries in Dermatology : how do we identify important safety issues as quickly as possible ? (2011) (0)
- Androgen effects on the skin (2015) (0)
- 33892 Telehealth use at a specialty hidradenitis suppurativa clinic during the COVID-19 pandemic (2022) (0)
- Reply to: "Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment". (2019) (0)
- "Useless information" : Oscar Wilde against the new journalism (2007) (0)
- Clinical Evaluation (2022) (0)
- Understanding patient engagement in psoriasis treatment (2018) (0)
- PSS16 SUSTAINED IMPROVEMENT IN SKIN DISEASE-SPECIFIC QUALITY OF LIFE IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS RECEIVING USTEKINUMAB MAINTENANCE THERAPY: LONG TERM RESULTS FROM PHOENIX 1 (2010) (0)
- PSOLAR: Update of a multicenter registry of patients with psoriasis who are candidates for systemic therapy including biologics (2011) (0)
- Telehealth Use by Age and Race at a Single Academic Medical Center During the COVID-19 Pandemic: Retrospective Cohort Study (Preprint) (2020) (0)
- Zoom Clinical Call Provides Help to Physicians About Palliative Care (2020) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Alexandra Boer Kimball?
Alexandra Boer Kimball is affiliated with the following schools:
